Updated on 13 March 2015
The deal marks the first private equity investment in Indonesia's fast growing pharmaceutical industry
Singapore: In collaboration with German development finance institution DEG, Singapore-based private equity firm has sealed a million dollar deal with its investment in Indonesia's top drug maker PT Soho Global Health (SGH).
The deal marks the first private equity investment in Indonesia's fast growing pharmaceutical industry. "The funds will be used to create access to innovative, differentiated drugs through in-licensing from developed markets, acquire strategic assets and support the growth of the medical device sector," said Quadria Capital in a statement.
SGH manufactures and markets natural medicines and over-the-counter drugs across Indonesia. SGH has established a loyal customer base through its broad product portfolio that includes household brands such as Curcuma Plus, Diapet, Fitkom and Laxing in the OTC market as well as Imboost, Asthin, Curvit and Oste in the prescription market.
The company has one of the strongest pharmaceutical network in the country, covering 80 percent hospitals and 90 percent pharmacies in Indonesia. SGH also recently entered into a strategic partnership with Fresenius Kabi to develop intravenous drugs and infusion solutions.